HighTower Advisors’s Phio Pharmaceuticals PHIO Stock Holding History

HighTower Advisors’s Portfolio PHIO Stock Details PHIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2	Closed	-$12K	–	2324
2018 Q3	$12K	Hold	2	–	–	﹤0.01%	2196
2018 Q2	$19K	Hold	2	–	–	﹤0.01%	2113
2018 Q1	$32K	Buy	+2	New	+$46K	﹤0.01%	2041

Other funds holding PHIO

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HighTower Advisors's PHIO Position: Q4 2018 in Review

HighTower Advisors sold out of Phio Pharmaceuticals (PHIO) in Q4 2018, closing a stake of 2 shares — an estimated $12K sold.

HighTower Advisors first reported a position in PHIO in Q1 2018 and held it in 3 quarters. The position peaked at $32K in Q1 2018. 7 funds tracked by Wall St. Rank hold PHIO as of Q4 2018.

HighTower Advisors reported no remaining Phio Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
HighTower Advisors sold 2 Phio Pharmaceuticals shares in Q4 2018, an estimated $12K.
HighTower Advisors first reported a position in Phio Pharmaceuticals in Q1 2018 and held it in 3 quarters.
HighTower Advisors's Phio Pharmaceuticals position peaked at $32K in Q1 2018.
7 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q4 2018.

Based on HighTower Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.